Avoro Capital Advisors LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Avoro Capital Advisors LLC reported 35 stock positions worth $6.9 billion. Its top holding was United Therapeutics (UTHR) at 14.9% of the portfolio, followed by Ascendis Pharma A/S (ASND, 10.9%) and Argenx SE - ADR (ARGX, 9.8%). Compared with Q2 2024, it sold out of 6, added to 10 and reduced 8. The biggest buy was Ascendis Pharma A/S (ASND, shares +19%) and the biggest sale an exit from Cerevel Therapeutics (CERE).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001633313
- Portfolio Value
- $6.9B (Q3 2024)
- SEC Filing
- 0001104659-24-118335 ↗ filed Nov 14, 2024
Holdings Value
Holdings 35 stocks · $6.9B
| UTHR United Therapeutics Corp. | 14.94% | 2,858,888 | $1.0B | No change |
| ASND Ascendis Pharma A/S | 10.86% | 4,988,888 | $744.9M | Add +18.9% |
| ARGX Argenx SE - ADR | 9.79% | 1,238,467 | $671.3M | No change |
| KRYS Krystal Biotech Inc. | 6.96% | 2,622,222 | $477.3M | Add +7.8% |
| MDGL Madrigal Pharmaceuticals Inc. | 6.28% | 2,029,000 | $430.6M | Reduce -1.3% |
| APLS Apellis Pharmaceuticals Inc. | 4.67% | 11,111,111 | $320.4M | No change |
| SRPT Sarepta Therapeutics Inc. | 4.65% | 2,555,555 | $319.2M | Reduce -14.8% |
| RNAM Avidity Biosciences Inc. | 4.60% | 6,875,000 | $315.8M | Add +5.7% |
| FOLD Amicus Therapeutics Inc. | 3.61% | 23,175,000 | $247.5M | Reduce -15.4% |
| ITCI Intra-Cellular Therapies Inc. | 3.25% | 3,050,000 | $223.2M | Add +1.7% |
| XENE Xenon Pharmaceuticals Inc. | 3.25% | 5,666,666 | $223.1M | No change |
| KYMR Kymera Therapeutics Inc. | 3.11% | 4,500,000 | $213.0M | Add +15.7% |
| VERA Vera Therapeutics Inc. | 2.78% | 4,309,590 | $190.5M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 2.51% | 8,888,888 | $172.2M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 2.09% | 2,038,015 | $143.3M | Reduce -55.3% |
| MLTX Moonlake Immunotherapeutics | 2.04% | 2,770,100 | $139.7M | Add +0.0% |
| PCVX Vaxcyte Inc. | 1.96% | 1,175,000 | $134.3M | Add +104.3% |
| SLNO Soleno Therapeutics Inc. | 1.61% | 2,181,000 | $110.1M | Add +4.3% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.31% | 11,865,000 | $90.2M | Reduce -5.6% |
| SNDX Syndax Pharmaceuticals Inc. | 1.09% | 3,888,437 | $74.9M | No change |
| OCUL Ocular Therapeutix Inc. | 1.02% | 8,060,000 | $70.1M | No change |
| KURA Kura Oncology Inc. | 1.01% | 3,541,505 | $69.2M | No change |
| MRUS Merus NV | 0.99% | 1,355,000 | $67.7M | No change |
| TRML Tourmaline Bio Inc. | 0.83% | 2,222,222 | $57.1M | No change |
| MNKD Mannkind Corp. | 0.80% | 8,750,000 | $55.0M | Reduce -0.1% |
| RARE Ultragenyx Pharmaceutical Inc. | 0.67% | 830,000 | $46.1M | No change |
| AUTL Autolus Therapeutics PLC | 0.65% | 12,345,678 | $44.8M | No change |
| IOVA Iovance Biotherapeutics Inc. | 0.58% | 4,240,000 | $39.8M | Reduce -63.8% |
| TSHA Taysha Gene Therapies Inc. | 0.55% | 18,650,000 | $37.5M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 0.45% | 5,790,236 | $30.7M | Add +27.7% |
| CGON CG Oncology Inc. | 0.39% | 700,000 | $26.4M | No change |
| DYN Dyne Therapeutics Inc. | 0.34% | 650,000 | $23.3M | Add +461.6% |
| SYRE Spyre Therapeutics Inc. | 0.26% | 598,600 | $17.6M | Reduce -67.5% |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 0.09% | 2,849,402 | $5.9M | No change |
| NGNE Neurogene Inc. | 0.01% | 22,029 | $924K | No change |
Options reported separately and not counted above: INSMED INC puts ($125K).
Portfolio Sells Q2 2024 → Q3 2024
| CERE Cerevel Therapeutics Holding | Sold out | 0.00% | −4.11 |
| XBI SS SPDR S&P Biotech ETF | Sold out | 0.00% | −3.75 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -55.3% | 2.09% | −2.91 |
| SRPT Sarepta Therapeutics Inc. | Reduce -14.8% | 4.65% | −1.66 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -1.3% | 6.28% | −1.39 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −1.29 |
| IOVA Iovance Biotherapeutics Inc. | Reduce -63.8% | 0.58% | −0.67 |
| VRCA Verrica Pharmaceuticals Inc. | Sold out | 0.00% | −0.39 |
| SYRE Spyre Therapeutics Inc. | Reduce -67.5% | 0.26% | −0.32 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −0.19 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.04 |
| FOLD Amicus Therapeutics Inc. | Reduce -15.4% | 3.61% | −0.01 |
| MNKD Mannkind Corp. | Reduce -0.1% | 0.80% | +0.19 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -5.6% | 1.31% | +0.28 |
Portfolio Buys Q2 2024 → Q3 2024
| ASND Ascendis Pharma A/S | Add +18.9% | 10.86% | +3.24 |
| KYMR Kymera Therapeutics Inc. | Add +15.7% | 3.11% | +1.56 |
| PCVX Vaxcyte Inc. | Add +104.3% | 1.96% | +1.38 |
| RNAM Avidity Biosciences Inc. | Add +5.7% | 4.60% | +1.07 |
| KRYS Krystal Biotech Inc. | Add +7.8% | 6.96% | +1.01 |
| ITCI Intra-Cellular Therapies Inc. | Add +1.7% | 3.25% | +0.52 |
| SLNO Soleno Therapeutics Inc. | Add +4.3% | 1.61% | +0.47 |
| MLTX Moonlake Immunotherapeutics | Add +0.0% | 2.04% | +0.41 |
| DYN Dyne Therapeutics Inc. | Add +461.6% | 0.34% | +0.29 |
| GLUE Monte Rosa Therapeutics Inc. | Add +27.7% | 0.45% | +0.22 |
Options Activity Q2 2024 → Q3 2024
| INSMED INC | put | New | 50,000 | $125K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $11.1B | UTHR, ASND, KRYS, MDGL, ARGX |
| Q1 2026 | 30 | $10.2B | UTHR, ASND, MDGL, KRYS, ARGX |
| Q4 2025Amended | 33 | $10.2B | UTHR, ASND, MDGL, ARGX, KRYS |
| Q3 2025 | 30 | $7.7B | ASND, UTHR, MDGL, ARGX, KRYS |
| Q2 2025 | 30 | $5.7B | ASND, UTHR, ARGX, MDGL, KRYS |
| Q1 2025 | 33 | $6.4B | UTHR, ASND, ARGX, MDGL, KRYS |
| Q4 2024 | 39 | $7.1B | UTHR, ARGX, ASND, MDGL, KRYS |
| Q3 2024 | 35 | $6.9B | UTHR, ASND, ARGX, KRYS, MDGL |
| Q2 2024 | 41 | $7.5B | UTHR, MDGL, ASND, ARGX, SRPT |
| Q1 2024 | 46 | $8.6B | UTHR, APLS, ASND, SRPT, MDGL |